Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cardiovascular disease therapy - Resverlogix

Drug Profile

Research programme: cardiovascular disease therapy - Resverlogix

Alternative Names: RVX-408

Latest Information Update: 16 Jan 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Resverlogix Corporation
  • Class Small molecules
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 01 Jan 2015 No development reported - Preclinical for Cardiovascular disorders in USA (PO)
  • 19 Jan 2011 Preclinical development is ongoing in USA
  • 10 Dec 2007 The US FDA grants approval to Resverlogix to begin a phase I clinical trial for RVX 208
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top